JP2012519707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519707A5 JP2012519707A5 JP2011553146A JP2011553146A JP2012519707A5 JP 2012519707 A5 JP2012519707 A5 JP 2012519707A5 JP 2011553146 A JP2011553146 A JP 2011553146A JP 2011553146 A JP2011553146 A JP 2011553146A JP 2012519707 A5 JP2012519707 A5 JP 2012519707A5
- Authority
- JP
- Japan
- Prior art keywords
- epha3
- antibody
- cells
- cell
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 22
- 102000021607 EphA3 Receptor Human genes 0.000 claims 18
- 108010055191 EphA3 Receptor Proteins 0.000 claims 18
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 12
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 10
- 210000000130 stem cell Anatomy 0.000 claims 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 2
- 230000002071 myeloproliferative effect Effects 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102100033941 Ephrin-A5 Human genes 0.000 claims 1
- 101000925251 Homo sapiens Ephrin-A5 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15828509P | 2009-03-06 | 2009-03-06 | |
| US61/158,285 | 2009-03-06 | ||
| US16813009P | 2009-04-09 | 2009-04-09 | |
| US61/168,130 | 2009-04-09 | ||
| PCT/US2010/026413 WO2010102244A1 (en) | 2009-03-06 | 2010-03-05 | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015122537A Division JP2015231994A (ja) | 2009-03-06 | 2015-06-18 | ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519707A JP2012519707A (ja) | 2012-08-30 |
| JP2012519707A5 true JP2012519707A5 (OSRAM) | 2013-04-18 |
| JP5876728B2 JP5876728B2 (ja) | 2016-03-02 |
Family
ID=42370943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553146A Expired - Fee Related JP5876728B2 (ja) | 2009-03-06 | 2010-03-05 | ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 |
| JP2015122537A Pending JP2015231994A (ja) | 2009-03-06 | 2015-06-18 | ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015122537A Pending JP2015231994A (ja) | 2009-03-06 | 2015-06-18 | ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8834870B2 (OSRAM) |
| EP (1) | EP2403879A1 (OSRAM) |
| JP (2) | JP5876728B2 (OSRAM) |
| CN (1) | CN102405237A (OSRAM) |
| AU (1) | AU2010221159B2 (OSRAM) |
| CA (1) | CA2753995A1 (OSRAM) |
| EA (1) | EA201101241A1 (OSRAM) |
| NZ (1) | NZ594950A (OSRAM) |
| WO (1) | WO2010102244A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| WO2009023184A2 (en) * | 2007-08-10 | 2009-02-19 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| JP2013508292A (ja) | 2009-10-14 | 2013-03-07 | カロバイオス ファーマシューティカルズ インコーポレイティッド | ＥｐｈＡ３に対する抗体 |
| US11536713B2 (en) | 2009-12-25 | 2022-12-27 | Chugai Seiyaku Kabushiki Kaisha | Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein |
| JP6230789B2 (ja) | 2010-10-06 | 2017-11-15 | 中外製薬株式会社 | 癌幹細胞集団及びその作製方法 |
| GB201021623D0 (en) * | 2010-12-21 | 2011-02-02 | Isis Innovation | Detection of acute myeloid leukaemia |
| CN104254340A (zh) * | 2011-08-12 | 2014-12-31 | 卡罗生物制药股份有限公司 | 通过靶向骨髓中异常血管系统上表达的EphA3来治疗血液增殖性疾病的方法 |
| WO2013035824A1 (ja) | 2011-09-07 | 2013-03-14 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞の分離 |
| EP2772268B8 (en) | 2011-10-28 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
| KR102775902B1 (ko) | 2013-12-17 | 2025-03-06 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| IL291937A (en) * | 2019-10-09 | 2022-06-01 | Council Queensland Inst Medical Res | Targeting epha3 and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0590030B1 (en) | 1991-06-21 | 2004-09-29 | The Walter and Eliza Hall Institute of Medical Research | A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| NO175798C (no) | 1992-07-22 | 1994-12-07 | Sinvent As | Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2367212A1 (en) | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| AU3672800A (en) | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1094110A1 (en) | 1999-10-21 | 2001-04-25 | Leadd B.V. | Apoptosis inducing proteinaceous substance |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| KR101060361B1 (ko) | 2002-03-19 | 2011-08-29 | 스티칭 디엔스트 랜드보위쿤디그 온데조에크 | 식물에서 글리칸 프로세싱의 최적화 |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| EP1784424A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | EPH RECEPTOR BINDING FC VARIANTS HAVING CELLULAR CELLULAR ACTIVITY DEPENDENT ANTIBODIES |
| US8222253B2 (en) * | 2004-10-23 | 2012-07-17 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
| AU2005306502B2 (en) | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| DK1974040T3 (da) | 2006-01-17 | 2012-12-17 | Synthon Biopharmaceuticals Bv | Sammensætninger og fremgangsmåder til humanisering og optimering af N-glycanet i planter. |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| CA2679986C (en) * | 2007-03-08 | 2018-03-06 | Martin Lackmann | Epha3 antibodies for the treatment of solid tumors |
-
2010
- 2010-03-05 EP EP10708675A patent/EP2403879A1/en not_active Withdrawn
- 2010-03-05 NZ NZ594950A patent/NZ594950A/xx not_active IP Right Cessation
- 2010-03-05 JP JP2011553146A patent/JP5876728B2/ja not_active Expired - Fee Related
- 2010-03-05 AU AU2010221159A patent/AU2010221159B2/en not_active Ceased
- 2010-03-05 CA CA2753995A patent/CA2753995A1/en not_active Abandoned
- 2010-03-05 US US12/718,768 patent/US8834870B2/en active Active
- 2010-03-05 WO PCT/US2010/026413 patent/WO2010102244A1/en not_active Ceased
- 2010-03-05 CN CN2010800176719A patent/CN102405237A/zh active Pending
- 2010-03-05 EA EA201101241A patent/EA201101241A1/ru unknown
-
2014
- 2014-08-29 US US14/473,821 patent/US20140370010A1/en not_active Abandoned
-
2015
- 2015-06-18 JP JP2015122537A patent/JP2015231994A/ja active Pending
-
2016
- 2016-09-14 US US15/265,625 patent/US20170226227A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519707A5 (OSRAM) | ||
| CO6260105A2 (es) | Anticuerpos humanos contra cd20 humano y metodo para utilizarlos | |
| NZ740686A (en) | Therapeutic cd47 antibodies | |
| EA201070596A1 (ru) | Гуманизированные антитела против tl1a | |
| MX2017002875A (es) | Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1. | |
| WO2011139974A3 (en) | Anti-pai-1 antibodies and methods of use thereof | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| JP2014240385A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2018534933A5 (OSRAM) | ||
| JP2015520758A5 (OSRAM) | ||
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2017507652A5 (OSRAM) | ||
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| NZ739750A (en) | Anti-tigit antibodies and methods of use | |
| JP2013198490A5 (OSRAM) | ||
| EA201791876A1 (ru) | Моноклональные антитела к прогастрину и их применение | |
| NO20091712L (no) | Nye anti-CD38-antistoffer for behandling av cancer | |
| JP2013538057A5 (OSRAM) | ||
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| RU2016101109A (ru) | Медицинское применение агонистов cd38 | |
| JP2008537778A5 (OSRAM) | ||
| JP2008507530A5 (OSRAM) | ||
| WO2016022939A8 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use |